InMed Pharmaceuticals (INM) Competitors

$1.60 +0.92 (+135.05%)

Closing price 05/19/2026 04:00 PM Eastern

Extended Trading

$1.69 +0.09 (+5.56%)

As of 05/19/2026 07:59 PM Eastern

INM vs. CALC, MTEX, GNPX, LIMN, and BFRG

Should you buy InMed Pharmaceuticals stock or one of its competitors? MarketBeat compares InMed Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with InMed Pharmaceuticals include CalciMedica (CALC), Mannatech (MTEX), Genprex (GNPX), Liminatus Pharma (LIMN), and Bullfrog AI (BFRG). These companies are all part of the "pharmaceutical products" industry.

How does InMed Pharmaceuticals compare to CalciMedica?

CalciMedica (NASDAQ:CALC) and InMed Pharmaceuticals (NASDAQ:INM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

CalciMedica has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -132.87%. InMed Pharmaceuticals' return on equity of -80.85% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CalciMedica	N/A	-863.40%	-144.33%
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%

20.1% of InMed Pharmaceuticals shares are owned by institutional investors. 41.6% of CalciMedica shares are owned by company insiders. Comparatively, 0.9% of InMed Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

InMed Pharmaceuticals has higher revenue and earnings than CalciMedica. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CalciMedica	N/A	N/A	-$29.56M	-$1.31	N/A
InMed Pharmaceuticals	$4.94M	1.07	-$8.16M	-$2.89	N/A

In the previous week, InMed Pharmaceuticals had 12 more articles in the media than CalciMedica. MarketBeat recorded 18 mentions for InMed Pharmaceuticals and 6 mentions for CalciMedica. CalciMedica's average media sentiment score of 0.50 beat InMed Pharmaceuticals' score of 0.25 indicating that CalciMedica is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CalciMedica	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
InMed Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	16 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CalciMedica currently has a consensus target price of $10.00, suggesting a potential upside of 1,519.70%. Given CalciMedica's stronger consensus rating and higher probable upside, equities analysts clearly believe CalciMedica is more favorable than InMed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CalciMedica	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

CalciMedica has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market. Comparatively, InMed Pharmaceuticals has a beta of 0.57, meaning that its stock price is 43% less volatile than the broader market.

Summary

CalciMedica beats InMed Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does InMed Pharmaceuticals compare to Mannatech?

Mannatech (NASDAQ:MTEX) and InMed Pharmaceuticals (NASDAQ:INM) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk.

13.0% of Mannatech shares are owned by institutional investors. Comparatively, 20.1% of InMed Pharmaceuticals shares are owned by institutional investors. 41.5% of Mannatech shares are owned by insiders. Comparatively, 0.9% of InMed Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Mannatech has a net margin of -11.97% compared to InMed Pharmaceuticals' net margin of -132.87%. InMed Pharmaceuticals' return on equity of -80.85% beat Mannatech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mannatech	-11.97%	-2,383.34%	-40.24%
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mannatech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Mannatech has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market. Comparatively, InMed Pharmaceuticals has a beta of 0.57, indicating that its stock price is 43% less volatile than the broader market.

In the previous week, InMed Pharmaceuticals had 15 more articles in the media than Mannatech. MarketBeat recorded 18 mentions for InMed Pharmaceuticals and 3 mentions for Mannatech. InMed Pharmaceuticals' average media sentiment score of 0.25 beat Mannatech's score of -0.32 indicating that InMed Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mannatech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
InMed Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	16 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

InMed Pharmaceuticals has lower revenue, but higher earnings than Mannatech. Mannatech is trading at a lower price-to-earnings ratio than InMed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mannatech	$108.04M	0.08	-$15.21M	-$6.71	N/A
InMed Pharmaceuticals	$4.94M	1.07	-$8.16M	-$2.89	N/A

Summary

InMed Pharmaceuticals beats Mannatech on 8 of the 13 factors compared between the two stocks.

How does InMed Pharmaceuticals compare to Genprex?

InMed Pharmaceuticals (NASDAQ:INM) and Genprex (NASDAQ:GNPX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Genprex has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -132.87%. InMed Pharmaceuticals' return on equity of -80.85% beat Genprex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%
Genprex	N/A	-247.32%	-176.73%

InMed Pharmaceuticals has a beta of 0.57, meaning that its stock price is 43% less volatile than the broader market. Comparatively, Genprex has a beta of -0.94, meaning that its stock price is 194% less volatile than the broader market.

20.1% of InMed Pharmaceuticals shares are held by institutional investors. Comparatively, 14.1% of Genprex shares are held by institutional investors. 0.9% of InMed Pharmaceuticals shares are held by insiders. Comparatively, 0.3% of Genprex shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

InMed Pharmaceuticals has higher revenue and earnings than Genprex. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMed Pharmaceuticals	$4.94M	1.07	-$8.16M	-$2.89	N/A
Genprex	N/A	N/A	-$16.23M	-$26.50	N/A

In the previous week, InMed Pharmaceuticals had 13 more articles in the media than Genprex. MarketBeat recorded 18 mentions for InMed Pharmaceuticals and 5 mentions for Genprex. Genprex's average media sentiment score of 0.84 beat InMed Pharmaceuticals' score of 0.25 indicating that Genprex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InMed Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	16 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Genprex	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

InMed Pharmaceuticals beats Genprex on 9 of the 12 factors compared between the two stocks.

How does InMed Pharmaceuticals compare to Liminatus Pharma?

Liminatus Pharma (NASDAQ:LIMN) and InMed Pharmaceuticals (NASDAQ:INM) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.

InMed Pharmaceuticals has higher revenue and earnings than Liminatus Pharma. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than Liminatus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liminatus Pharma	N/A	N/A	-$10.21M	-$0.44	N/A
InMed Pharmaceuticals	$4.94M	1.07	-$8.16M	-$2.89	N/A

20.1% of InMed Pharmaceuticals shares are owned by institutional investors. 0.9% of InMed Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Liminatus Pharma has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -132.87%. Liminatus Pharma's return on equity of 0.00% beat InMed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liminatus Pharma	N/A	N/A	-299.79%
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%

In the previous week, InMed Pharmaceuticals had 17 more articles in the media than Liminatus Pharma. MarketBeat recorded 18 mentions for InMed Pharmaceuticals and 1 mentions for Liminatus Pharma. Liminatus Pharma's average media sentiment score of 1.38 beat InMed Pharmaceuticals' score of 0.25 indicating that Liminatus Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Liminatus Pharma	Positive
InMed Pharmaceuticals	Neutral

Summary

InMed Pharmaceuticals beats Liminatus Pharma on 6 of the 11 factors compared between the two stocks.

How does InMed Pharmaceuticals compare to Bullfrog AI?

InMed Pharmaceuticals (NASDAQ:INM) and Bullfrog AI (NASDAQ:BFRG) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

InMed Pharmaceuticals has a beta of 0.57, indicating that its share price is 43% less volatile than the broader market. Comparatively, Bullfrog AI has a beta of -3, indicating that its share price is 400% less volatile than the broader market.

Bullfrog AI has lower revenue, but higher earnings than InMed Pharmaceuticals. Bullfrog AI is trading at a lower price-to-earnings ratio than InMed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMed Pharmaceuticals	$4.94M	1.07	-$8.16M	-$2.89	N/A
Bullfrog AI	$120K	65.41	-$6.50M	-$0.54	N/A

In the previous week, InMed Pharmaceuticals had 17 more articles in the media than Bullfrog AI. MarketBeat recorded 18 mentions for InMed Pharmaceuticals and 1 mentions for Bullfrog AI. Bullfrog AI's average media sentiment score of 1.38 beat InMed Pharmaceuticals' score of 0.25 indicating that Bullfrog AI is being referred to more favorably in the news media.

Company	Overall Sentiment
InMed Pharmaceuticals	Neutral
Bullfrog AI	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bullfrog AI	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

20.1% of InMed Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.0% of Bullfrog AI shares are owned by institutional investors. 0.9% of InMed Pharmaceuticals shares are owned by company insiders. Comparatively, 25.2% of Bullfrog AI shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Bullfrog AI has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -132.87%. InMed Pharmaceuticals' return on equity of -80.85% beat Bullfrog AI's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%
Bullfrog AI	N/A	-217.80%	-174.57%

Summary

InMed Pharmaceuticals beats Bullfrog AI on 7 of the 13 factors compared between the two stocks.

Get InMed Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INM vs. The Competition

Export

Metric	InMed Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.26M	$2.99B	$6.24B	$12.23B
Dividend Yield	N/A	1.96%	2.80%	5.32%
P/E Ratio	-0.55	17.04	20.79	25.05
Price / Sales	1.07	251.21	531.21	72.68
Price / Cash	N/A	57.15	43.09	54.25
Price / Book	0.77	4.39	9.81	6.83
Net Income	-$8.16M	$74.99M	$3.55B	$335.69M
7 Day Performance	151.97%	-5.15%	-2.11%	-2.15%
1 Month Performance	126.31%	-8.25%	-4.14%	-2.47%
1 Year Performance	-47.54%	26.23%	28.35%	27.13%

InMed Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INM InMed Pharmaceuticals	1.0753 of 5 stars	$1.60 +135.1%	N/A	-42.0%	$2.26M	$4.94M	N/A	10	Trending News Gap Up High Trading Volume
CALC CalciMedica	2.7786 of 5 stars	$0.60 -0.1%	$13.00 +2,063.1%	-66.8%	$9.46M	N/A	N/A	30	News Coverage Analyst Revision
MTEX Mannatech	0.1864 of 5 stars	$4.88 flat	N/A	-57.6%	$9.42M	$108.04M	N/A	250	News Coverage Earnings Report
GNPX Genprex	0.901 of 5 stars	$0.89 +0.7%	N/A	-94.2%	$9.24M	N/A	N/A	20	Earnings Report
LIMN Liminatus Pharma	1.0051 of 5 stars	$0.21 flat	N/A	N/A	$9.20M	N/A	N/A	N/A	Earnings Report Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INM) was last updated on 5/20/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

InMed Pharmaceuticals (INM) Competitors

INM vs. CALC, MTEX, GNPX, LIMN, and BFRG

How does InMed Pharmaceuticals compare to CalciMedica?

Summary

How does InMed Pharmaceuticals compare to Mannatech?

Summary

How does InMed Pharmaceuticals compare to Genprex?

Summary

How does InMed Pharmaceuticals compare to Liminatus Pharma?

Summary

How does InMed Pharmaceuticals compare to Bullfrog AI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INM vs. The Competition

InMed Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

InMed Pharmaceuticals (INM) Competitors

INM vs. CALC, MTEX, GNPX, LIMN, and BFRG

How does InMed Pharmaceuticals compare to CalciMedica?

Is CALC or INM more profitable?

Do institutionals and insiders hold more shares of CALC or INM?

Which has better earnings & valuation, CALC or INM?

Does the media prefer CALC or INM?

Do analysts rate CALC or INM?

Which has more risk & volatility, CALC or INM?

Summary

How does InMed Pharmaceuticals compare to Mannatech?

Do insiders and institutionals hold more shares of MTEX or INM?

Is MTEX or INM more profitable?

Do analysts rate MTEX or INM?

Which has more risk and volatility, MTEX or INM?

Does the media prefer MTEX or INM?

Which has preferable valuation & earnings, MTEX or INM?

Summary

How does InMed Pharmaceuticals compare to Genprex?

Do analysts prefer INM or GNPX?

Is INM or GNPX more profitable?

Which has more volatility & risk, INM or GNPX?

Do insiders & institutionals believe in INM or GNPX?

Which has better earnings & valuation, INM or GNPX?

Does the media favor INM or GNPX?

Summary

How does InMed Pharmaceuticals compare to Liminatus Pharma?

Which has preferable earnings & valuation, LIMN or INM?

Do institutionals and insiders believe in LIMN or INM?

Do analysts recommend LIMN or INM?

Is LIMN or INM more profitable?

Does the media prefer LIMN or INM?

Summary

How does InMed Pharmaceuticals compare to Bullfrog AI?

Which has more volatility & risk, INM or BFRG?

Which has better earnings and valuation, INM or BFRG?

Does the media favor INM or BFRG?

Do analysts recommend INM or BFRG?

Do insiders and institutionals have more ownership in INM or BFRG?

Is INM or BFRG more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INM vs. The Competition

InMed Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools